Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension (Q84968455)
Jump to navigation
Jump to search
scientific article published on 01 October 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension |
scientific article published on 01 October 2012 |
Statements
Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension (English)
A H Barnett
S Patel
R Harper
R Toorawa
S Thiemann
1 October 2012